생물정신의학 (Korean Journal of Biological Psychiatry)
- 제6권1호
- /
- Pages.96-101
- /
- 1999
- /
- 1225-8709(pISSN)
- /
- 2005-7571(eISSN)
기분부전장애에서 Moclobemide와 Amitriptyline의 치료 효과와 내약성 비교 연구
Efficacy and Tolerability of Moclobemide Compared with Amitriptyline in Dysthymic Disorder
-
이민수
(고려대학교 의과대학 신경정신과학교실) ;
- 남종원 (고려대학교 의과대학 신경정신과학교실) ;
- 유승호 (건국대학교 의과대학 정신과학교실) ;
- 차지현 (고려대학교 의과대학 신경정신과학교실) ;
- 김용구 (고려대학교 의과대학 신경정신과학교실)
-
Lee, Min Soo
(Department of Neuropsychiatry, College of Medicine, Korea University) ;
- Nam, Jong Won (Department of Neuropsychiatry, College of Medicine, Korea University) ;
- Ryu, Seung Ho (Department of Psychiatry, College of Medicine, Konkuk University) ;
- Cha, Ji Hyun (Department of Neuropsychiatry, College of Medicine, Korea University) ;
- Kim, Yong Ku (Department of Neuropsychiatry, College of Medicine, Korea University)
- 발행 : 1999.06.25
초록
Background : Since dysthymia begins in late childhood or adolescence and has a chronic course, long-term pharmacotherapy may be required. New generation antidepressant, moclobemide, with more acceptable side effect profiles, is effective in the treatment of dysthymia. The main objective of this study was to determine whether they exhibit comparable efficacy and tolerability in dysthymia to amitriptyline. Method and Materials : The efficacy and tolerability of the moclobemide and amitriptyline, were compared in a eight-week single-centre double-blind study in patients(n=37) with dysthymia using he HAMD-17, the Clinical Global Impression Scale(CGI), the Montgomery-Asberg Depression Rating Scale (MADRS), Efficacy Index-Therapeutic Index(EITE), 4-point Index Side Effect Scale(4-PISES), and Efficacy Index- Side Effect Scale(EISE). Results : A total of 37 patients entered the study, 19 were randomly assigned to the moclobemide group and 18 to be amitriptyline group. Demo-graphic and illness characteristics were similar in both groups. There were no significant difference between two groups at the total 17-HDRS score, the HAMD-17% improvement, the total MADRS score, CGI response, and the EITE. In the comparison of EISE between two groups, the scores of the moclobemide group were relatively lower than the amitriptylinen group in full treatment. And the differences were significant(moclobemide group